17.53 0.00 (0.00%)
After hours: 6:46PM EST
|Bid||17.52 x 4000|
|Ask||17.89 x 4000|
|Day's range||17.17 - 17.77|
|52-week range||16.63 - 36.46|
|Beta (3Y monthly)||1.76|
|PE ratio (TTM)||194.78|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.
Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
Mylan (MYL) delivered earnings and revenue surprises of 2.63% and -2.39%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Mylan, which posted higher-than-expected third-quarter profit with the help of cost constraints, said it would reassess products it sells outside United States and had nearly completed its review of U.S. products. The review process should not affect net profit, President Rajiv Malik said on a conference call with analysts. Mylan in July agreed to merge with Pfizer Inc's Upjohn unit that sells off-patent branded drugs.
Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.
Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.
During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q3 sales, genericization of some older drugs are likely to have hurt the same.
Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.
The U.S. Supreme Court on Monday declined to hear Acorda Therapeutics Inc's appeal of a lower court ruling that allowed generic versions of its multiple sclerosis treatment Ampyra and caused the drug's sales to plummet. The justices refused to review a September 2018 decision by the U.S. Court of Appeals for the Federal Circuit to cancel Acorda's patents covering Ampyra, a ruling the Ardsley, New York-based company and the pharmaceutical industry portrayed as a threat to innovation and bad for patients. According to Acorda, Ampyra was the first drug approved to improve walking in people with multiple sclerosis, an incurable and potentially disabling disease of the brain and spinal cord that can lead to symptoms including pain, visual impairments and difficulty walking.
The SEC on Friday said Mylan kept investors in the dark when it failed to disclose or set aside money for the two-year probe by the U.S. Department of Justice, prior to announcing a $465 million settlement in October 2016. In a statement, Mylan called the SEC civil settlement "the right course of action," and said it was committed to the "highest levels of integrity" when communicating with investors and making disclosures in public filings.
Mylan NV has agreed to pay a $30 million fine to settle U.S. Securities and Exchange Commission charges it hid from investors the impact of a federal probe into the drugmaker's overbilling the government for its EpiPen allergy treatment. The SEC on Friday said Mylan kept investors in the dark when it failed to disclose or set aside money for the two-year probe by the U.S. Department of Justice, prior to announcing a $465 million settlement in October 2016. In a statement, Mylan called the SEC civil settlement "the right course of action," and said it was committed to the "highest levels of integrity" when communicating with investors and making disclosures in public filings.